NICE is urged to make drug companies supply all trial dataBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8294 (Published 05 December 2012) Cite this as: BMJ 2012;345:e8294
- Adrian O’Dowd
The drug regulator the National Institute for Health and Clinical Excellence should put more pressure on drug companies to produce all data in trials, MPs have said.
MPs on the parliamentary health select committee challenged the leaders of NICE to take action to tackle the issue of unpublished data from drug trials at an evidence session on Tuesday 4 December.
Michael Rawlins, NICE’s chairman, who will retire from the post next April, and its chief executive, Andrew Dillon, appeared before the Health Committee as part of its inquiry into the institute.
In October the BMJ published an open letter from its editor in chief, Fiona Godlee, to the drug company Roche saying that researchers were still denied …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial